U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07557004) titled 'A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.' on April 15.
Brief Summary: Evaluate the efficacy and safety of the SH3765 tablet combined with fulvestrant in the treatment of patients with advanced HR-positive breast cancer
Study Start Date: Sept. 30, 2025
Study Type: INTERVENTIONAL
Condition:
HR+ / HER2- Advanced Breast Cancer
Intervention:
DRUG: SH3765+Fulvestrant
Drug1: SH3765 will be administered orally twice daily on an intermittent dosing schedule with treatment on Days 1 to 4 each week of a 28-day treatment cycle. The dosage is 40 mg or 60mg twice daily (B...